OptimizeRx Third-Quarter Revenue Falls 17 Percent to 21.6 Million Dollars: Net Income of 1.2 Million Dollars, Adjusted EBITDA of 6.3 Million Dollars, Full-Year Revenue Guidance Updated to 87 to 93 Million Dollars
Waltham, Massachusetts — OptimizeRx Corp. reported its results for the third quarter ended September 30, 2026, via GlobeNewswire on November 11, 2026. The company provides healthcare technology solutions that help life sciences companies reach and engage healthcare professionals and patients. All figures are taken from the body of the company official results release.
Revenue decreased 17 percent to 21.6 million dollars in the third quarter of 2026, compared with 26.1 million dollars in the third quarter of 2025. GAAP net income was 1.2 million dollars, or 0.06 dollars per basic and diluted share, compared with GAAP net income of 0.8 million dollars, or 0.04 dollars per share, in the third quarter of 2025.
On a non-GAAP basis, net income was 3.8 million dollars, or 0.20 dollars per diluted share, compared with 3.1 million dollars, or 0.16 dollars per diluted share, in the prior-year quarter. Adjusted EBITDA was 6.3 million dollars, compared with 5.1 million dollars in the third quarter of 2025.
The company updated its fiscal 2026 guidance and now expects revenue of 87 million to 93 million dollars, with adjusted EBITDA guidance unchanged at 21 million to 25 million dollars. All figures follow the body of the OptimizeRx official results release, and media expectations were not used as a source.
Source: OptimizeRx
Published by GSM · USA (original Chinese edition)
Photo: 图：图中是一家证券交易所的交易大厅与行情屏。图中是交易所大厅的实物照片，为医疗科技业绩题材通用配图，非该公司场所。ehnmark，CC BY 2.0，经Wikimedia Commons。 / Photo: file photo. ehnmark, CC BY 2.0, via Wikimedia Commons.
